1. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.
- Author
-
Jeannot E, Latouche A, Bonneau C, Calméjane MA, Beaufort C, Ruigrok-Ritstier K, Bataillon G, Larbi Chérif L, Dupain C, Lecerf C, Popovic M, de la Rochefordière A, Lecuru F, Fourchotte V, Jordanova ES, von der Leyen H, Tran-Perennou C, Legrier ME, Dureau S, Raizonville L, Bello Roufai D, Le Tourneau C, Bièche I, Rouzier R, Berns EMJJ, Kamal M, and Scholl S
- Subjects
- Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Female, Humans, Middle Aged, Papillomavirus Infections complications, Prospective Studies, Uterine Cervical Neoplasms therapy, Young Adult, Alphapapillomavirus genetics, Biomarkers, Tumor blood, DNA, Viral blood, Early Detection of Cancer, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local virology, Neoplasm, Residual blood, Neoplasm, Residual virology, Papillomavirus Infections blood, Uterine Cervical Neoplasms blood, Uterine Cervical Neoplasms virology
- Abstract
Purpose: Almost all cervical cancers are caused by human papillomavirus (HPV) and patients with advanced stage are at high risk for relapse. Circulating HPV DNA (HPV ctDNA) may serve as a residual tumor marker at the end of chemoradiation or to predict relapse during the follow-up period., Experimental Design: We analyzed serum samples from 94 HPV16- or HPV18-related CCs from the BioRAIDs prospective cohort. Samples were collected before and after treatment and during an 18-month follow-up period. Using digital droplet PCR (ddPCR), we assessed the relevance of circulating HPV E7 gene as a marker for residual disease compared to HPV integration site and PIK3CA mutations. Finally, the prognostic impact of circulating HPV E7 gene was assessed with its prediction value of relapse., Results: HPV E7 gene was the most sensitive tumor marker, superior to both HPV integration sites and PIK3CA mutations in serum. Circulating HPV DNA (HPV ctDNA) was detected in 63% (59/94) of patients, before treatment. HPV ctDNA detection in serum sample was associated with high FIGO stage ( P = 0.02) and para-aortic lymph node involvement ( P = 0.01). The level of HPV ctDNA was positively correlated with HPV copy number in the tumor ( R = 0.39, P < 0.001). Complete clearance of HPV ctDNA by the end of treatment was significantly associated with a longer PFS ( P < 0.0001). Patients with persistent HPV ctDNA in serum relapsed with a median time of 10 months (range, 2-15) from HPV ctDNA detection., Conclusions: HPV ctDNA detection is a useful marker to predict relapse in cervical cancer. See related commentary by Wentzensen and Clarke, p. 5733 ., (©2021 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF